Nifediac CC and Polatuzumab vedotin
Determining the interaction of Nifediac CC and Polatuzumab vedotin and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with ketoconazole, a potent CYP450 3A4 inhibitor, is predicted to increase unconjugated MMAE exposure (AUC) by 45% according to the product labeling. No data are available for other, less potent CYP450 3A4 inhibitors. MANAGEMENT: Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors. Patients should be monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling. References "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with ketoconazole, a potent CYP450 3A4 inhibitor, is predicted to increase unconjugated MMAE exposure (AUC) by 45% according to the product labeling. No data are available for other, less potent CYP450 3A4 inhibitors.
MANAGEMENT: Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors. Patients should be monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling.
- "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.
Generic Name: nifedipine
Brand name: Adalat CC, Afeditab CR, Nifediac CC, Nifedical XL, Procardia, Procardia XL, Adalat
Synonyms: Nifediac CC (Oral)
Generic Name: polatuzumab vedotin
Brand name: Polivy
Synonyms: Polatuzumab Vedotin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Nifediac CC-Polatuzumab Vedotin-piiq
- Nifediac CC-Polio vaccine, inactivated
- Nifediac CC-Poliovirus Vaccine (Inactivated)
- Nifediac CC-Poliovirus vaccine, inactivated Injection
- Nifediac CC-Polivy
- Nifediac CC-Polmon
- Polatuzumab vedotin-Nifedical XL
- Polatuzumab vedotin-Nifedipine
- Polatuzumab vedotin-Nifedipine Capsules
- Polatuzumab vedotin-Nifedipine Extended-Release Tablets
- Polatuzumab vedotin-Niferex
- Polatuzumab vedotin-Niferex Elixir